|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, THS reduced mRNA expression of the proinflammatory cytokines, TNF-α, IL-6, and IL-1β and increased synapse-associated proteins (synaptophysin and postsynaptic density protein 95) in the hippocampus of AD mice.
|
31244052 |
2019 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
BBR promoted the expression of synaptophysin, post-synaptic density protein 95 and p-CREB(Ser133) in the AD brain, compared with the model mice.
|
30873920 |
2019 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Post-synaptic density protein 95 (PSD-95) and synaptophysin levels in the hippocampus were also effectively restored following the procedure in AD mice.
|
30958382 |
2019 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Levels of synaptophysin were enhanced, demonstrating protection from synaptic loss that is observed in AD.
|
29050859 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Heterochronic parabiosis (shared blood circulation) of AD transgenic mice with young healthy mice did not reduce amyloidosis and microglial activation in AD mice, but reversed the loss of synaptophysin and calbindin (critical synaptic proteins, indicators of cognitive decline in AD) in the dentate gyrus, and the abnormal expression, in the hippocampus, of many genes involved in key neuronal signaling pathways.
|
28384033 |
2018 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Additionally, the AD model‑induced decrease in phosphorylated (p) protein kinase B (p‑Akt), p‑glycogen synthase kinase 3β (p‑GSK3β), post‑synaptic density 95 and synaptophysin expression was reversed.
|
29257340 |
2018 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
GM-CSF treatment in AD mice reduced brain amyloidosis, increased plasma Aβ, and rescued cognitive impairment with increased hippocampal expression of calbindin and synaptophysin and increased levels of doublecortin-positive cells in the dentate gyrus.
|
29573847 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, the aim of this study was to investigate the preventive effects of anandamide (<i>N</i>-arachidonoylethanolamine, AEA) on multiple cognitive deficits and on the levels of synaptic proteins (syntaxin 1, synaptophysin and synaptosomal-associated protein, SNAP-25), cannabinoid receptor type 1 (CB<sub>1</sub>) and molecules related to p-tau degradation machinery (heat shock protein 70, HSP70), and Bcl2-associated athanogene (BAG2) in an AD-like sporadic dementia model in rats using intracerebroventricular (icv) injection of streptozotocin (STZ).
|
30333717 |
2018 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Golgi staining and immunohistochemical staining revealed that blockage of the β<sub>2</sub>-adrenergic receptor by ICI treatment decreased the number of dendritic branches, and ICI treatment in AD-TG mice decreased the expression of hippocampal synaptophysin and synapsin 1.
|
29089997 |
2017 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The anesthesia/surgery induced neither reduction in freezing time in FCS nor decreased hippocampus levels of PSD-95 and SVP in the AD Tg plus CypD KO mice.
|
28269788 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In addition, Ebselen mitigated the decrease of synaptic proteins including synaptophysin and postsynaptic density protein 95 in AD model cells and neurons.
|
28502066 |
2017 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Compared to non-AD control cybrids, AD cybrid cells showed synaptic loss which was evidenced by a significant reduction in expression of two synaptic marker proteins: synaptophysin (presynaptic marker) and postsynaptic density protein-95, and neuronal proteins (MAP-2 and NeuN) upon neuronal differentiation.
|
28598851 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
DEGs including DNAJB1 and HSPA1A may be involved in both the processes, while CHGB, SYP and SST may be important for the regulation of synaptic transmission to contribute to the progress and development of AD.
|
26935318 |
2016 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Repeated administration of hUBC-MSCs markedly promoted the expression of synaptic vesicle markers, including synaptophysin, which are downregulated in patients with AD.
|
26154268 |
2015 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to examine the presence of a synaptic lectican in AD tissue, determine if amyloid-β (Aβ) binds to lecticans purified from brain tissue, and examine how treatment of the same AD model with chondroitinase ABC would influence plaque burden and the density of the synaptic marker synaptophysin around plaques.
|
26337292 |
2015 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
DHA-PC and PSD-95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer's disease.
|
25410733 |
2014 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Synaptophysin (SYN) consistently declines with age and is further reduced with sporadic AD.
|
24927707 |
2014 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Upregulated mRNA and protein levels of neuroinflammatory and arachidonic acid (AA) markers with loss of synaptic markers (synaptophysin and drebrin) have been reported in brain tissue from AD and BD patients.
|
22760556 |
2012 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
F-spondin overexpression also suppressed endogenous levels of amyloid beta (Aβ(42)) in these mice and reduced Aβ plaque deposition while improving synaptophysin expression in transgenic mouse models of AD.
|
22863679 |
2012 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
For example, treatment with 2% AGE containing diet and SAC (20 mg/kg of diet) independently increased (∼70%) levels of SNAP25 and synaptophysin in Alzheimer's amyloid precursor protein-transgenic mice, of which the latter was significantly decreased in AD.
|
21166677 |
2011 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
We report that patients with FTLD have a significant increase in synaptophysin and depletion in SNAP-25 proteins compared to both control subjects and individuals with AD (P < 0.001).
|
21073671 |
2011 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
By using different housekeepers we confirmed that synaptophysin expression was down-regulated in AD cases, whereas glial fibrillary acidic protein expression was increased.
|
21044776 |
2010 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
When considering degeneration (ratio to synaptophysin and the post-synaptic marker PSD95), GR expression was similar between controls and AD, suggesting that GR loss was due to synaptic degeneration in AD.
|
20858975 |
2010 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In the study, the expression of clathrin regulatory proteins dynamin I, AP180, and synaptic vesicle protein synaptophysin in multiple brain regions of the patients with Alzheimer's disease (AD), the transgenic mice carrying the Swedish mutation of amyloid-β protein precursor (AβPP) 670/671 (AβPPSWE), and the rats injected by bilateral hippocampus with amyloid-β peptide (Aβ)1-42 were examined by immunohistochemistry and Nissl staining, Western blotting, and Real-time PCR, respectively.
|
20847448 |
2010 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
RGD |
Significant decreases in protein levels of dynamin I, AP180, and synaptophysin were observed in both AD patients and mice with AβPPSWE as compared to controls.
|
20847448 |
2010 |